false
0001730430
0001730430
2024-02-28
2024-02-28
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
February 28, 2024
Kiniksa Pharmaceuticals, Ltd.
(Exact name of Registrant as Specified in Its
Charter)
| Bermuda |
|
001-730430 |
|
98-1327726 |
(State or other jurisdiction of
incorporation or organization) |
|
(Commission
File Number) |
|
(I.R.S. Employer
Identification No.) |
Kiniksa Pharmaceuticals, Ltd.
Clarendon House
2 Church Street
Hamilton HM11, Bermuda
(808) 451-3453
(Address, zip code and telephone number,
including area code of principal executive offices)
Kiniksa Pharmaceuticals Corp.
100 Hayden Avenue
Lexington, MA, 02421
(781) 431-9100
(Address, zip code and telephone number,
including area code of agent for service)
N/A
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of
the Act:
| Title of each class |
|
Trading
Symbol(s) |
|
Name of each exchange on which
registered |
| Class A
Common Shares $0.000273235 par value |
|
KNSA |
|
The Nasdaq Stock Market LLC |
| |
|
|
|
(Nasdaq Global Select Market) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02. Results of Operations and Financial Condition.
On February 28, 2024, Kiniksa Pharmaceuticals, Ltd.
issued a press release announcing financial results for the fiscal year ended December 31, 2023. A copy of the press release is furnished
with this Current Report on Form 8-K as Exhibit 99.1.
The information contained in this Item 2.02 of this
Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall
it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of
any general incorporation language in such filing and except as expressly provided by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of
the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
KINIKSA PHARMACEUTICALS, LTD. |
| |
|
| Date: February 28, 2024 |
By: |
/s/ Madelyn Zeylikman |
| |
|
Madelyn Zeylikman |
| |
|
Senior Vice President, General Counsel and Secretary |
Exhibit 99.1
Kiniksa Pharmaceuticals
Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Portfolio Execution
– ARCALYST®
(rilonacept) Q4 2023 and full-year 2023 net product revenue of $71.2 million and $233.2 million, respectively –
– ARCALYST
2024 net product revenue expected to be $360 - $380 million, representing ~59% year-over-year growth at the midpoint –
– Abiprubart
Phase 2 rheumatoid arthritis data from Cohort 4 and a new development indication expected in April 2024 –
– Cash
reserves of $206.4 million expected to fund operations into at least 2027 –
– Conference
call and webcast scheduled for 8:30 am ET today –
HAMILTON,
BERMUDA – February 28, 2024 – Kiniksa
Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceutical company with a pipeline of immune-modulating
assets designed to target a spectrum of cardiovascular and autoimmune diseases, today reported fourth quarter and full-year 2023 financial
results and recent portfolio execution.
“Kiniksa meaningfully advanced
its business in 2023, primarily through robust ARCALYST net product revenue and collaboration profit growth. Significant growth remains
with ARCALYST in recurrent pericarditis, and we expect to help an increasing number of patients in the years ahead. Importantly, we anticipate
our robust commercial performance to contribute to our strong financial position and ability to drive growth across our business,”
said Sanj K. Patel, Chairman and Chief Executive Officer of Kiniksa. “Additionally, abiprubart recently showed clinical effect
in the first three cohorts of the Phase 2 trial in rheumatoid arthritis. We now expect to advance the asset into a Phase 2b trial in
a new indication, funding for which is included in our current cash runway guidance. Data from the fourth cohort of the abiprubart Phase
2 trial are intended to inform trial design and are expected in April.”
Portfolio and Collaboration Execution
ARCALYST (IL-1α and IL-1β
cytokine trap)
| • | ARCALYST
net product revenue was $71.2 million and $233.2 million for the fourth quarter and full-year
2023, respectively. |
| • | Since
launch in April 2021, more than 1,700 prescribers have written ARCALYST prescriptions
for recurrent pericarditis. |
| • | As
of the end of the fourth quarter of 2023, average total duration of ARCALYST therapy in recurrent
pericarditis had increased to approximately 23 months. |
| • | As
of the end of the fourth quarter of 2023, approximately 9% of the target 14,000 multiple-recurrence
patients were actively on ARCALYST treatment. |
| • | A
poster entitled Rilonacept Utilization in a Steroid-Sparing Paradigm for Recurrent Pericarditis:
Real-World Evidence Demonstrating Increased Adoption is planned to be presented at
the upcoming American College of Cardiology Scientific Session (ACC.24) in April 2024. |
Abiprubart (anti-CD40 monoclonal
antibody inhibitor of CD40-CD154 interaction)
| • | Kiniksa
previously announced topline data from the Phase 2 clinical trial of abiprubart in rheumatoid
arthritis, showing that the trial met its primary efficacy endpoint: change from baseline
in Disease Activity Score of 28 Joints Using C-reactive Protein (DAS28-CRP) versus placebo. |
| — | In Cohorts 1 and 2 (pharmacokinetic
lead-in), multiple doses of abiprubart were well-tolerated. |
| — | In Cohort 3, the abiprubart 5
mg/kg subcutaneous (SC) weekly dose level achieved statistical significance. The 5 mg/kg
SC biweekly dose level did not achieve statistical significance. Across both dose levels
abiprubart reduced Rheumatoid Factor, a clinical marker of disease activity and an autoantibody
pharmacodynamic marker of CD40 target engagement. Abiprubart was well-tolerated, with no
dose-related adverse experiences observed. |
| • | Kiniksa
expects data from the fourth cohort (Cohort 4) of the Phase 2 clinical trial in April 2024.
Cohort 4 will evaluate a fixed dose level administered as a single subcutaneous injection
once monthly. |
Mavrilimumab (monoclonal antibody
inhibitor targeting GM-CSFRα)
| • | Kiniksa
is evaluating potential partnership opportunities to advance development of mavrilimumab,
which has generated positive data in mid-stage clinical trials across multiple indications. |
Vixarelimab (monoclonal antibody
inhibitor of signaling through OSMRβ)
| • | In
the fourth quarter of 2023, Kiniksa recognized a $10.0 million development milestone related
to a second new indication under its global license agreement with Genentech, a member of
the Roche Group. |
Financial Results
| • | Total
revenue for the fourth quarter of 2023 was $83.4 million, compared to $61.9 million for the
fourth quarter of 2022. Total revenue for the full-year 2023 was $270.3 million, compared
to $220.2 million for the full-year 2022. |
| — | Total revenue for the fourth quarter
of 2023 included $12.2 million in license and collaboration revenue, compared to $21.9 million
for the fourth quarter of 2022. |
| — | Total revenue for the full-year
2023 included $37.1 million in license and collaboration revenue, compared to $97.7 million
for the full-year 2022. |
| • | Total
operating expenses for the fourth quarter of 2023 were $83.3 million, compared to $55.8 million
for the fourth quarter of 2022. Total operating expenses for the full-year 2023 were $295.5
million, compared to $210.4 million for the full-year 2022. |
| — | Total operating expenses for the
fourth quarter of 2023 included $16.9 million in collaboration expenses, which are driven
by ARCALYST collaboration profitability, compared to $7.5 million for the fourth quarter
of 2022. Total operating expenses for the full-year 2023 included $56.5 million in collaboration
expenses, compared to $24.1 million for the full-year 2022. |
| — | Total operating expenses for the
fourth quarter of 2023 included $7.8 million in non-cash, share-based compensation expense,
compared to $6.4 million for the fourth quarter of 2022. Total operating expense for the
full-year 2023 included $27.1 million in non-cash, share-based compensation expense, compared
to $25.1 million for the full-year 2022. |
| • | Net
income for the fourth quarter of 2023 was $25.2 million, compared to net income of $4.5 million
for the fourth quarter of 2022. Net income for the full-year 2023 was $14.1 million, compared
to net income of $183.4 million for the full-year 2022. |
| — | Net income for the fourth quarter
of 2023 included a tax benefit of $22.8 million, primarily due to the treatment of non-cash
deferred tax assets, compared to a tax expense of $2.4 million for the fourth quarter of
2022. |
| — | Net income for the full-year 2023
included a tax benefit of $30.7 million, compared to a tax benefit of $172.3 million for
the full-year 2022, both primarily due to the treatment of non-cash deferred tax assets. |
| • | As
of December 31, 2023, Kiniksa had $206.4 million of cash, cash equivalents, and short-term
investments and no debt. |
Financial
Guidance
| • | Kiniksa
expects 2024 ARCALYST net product revenue of between $360 million and $380 million. |
| • | Kiniksa
expects that its cash, cash equivalents, and short-term investments will fund its current
operating plan into at least 2027. |
Conference
Call Information
| • | Kiniksa
will host a conference call and webcast at 8:30 a.m. Eastern Time on Wednesday, February 28,
2024, to discuss fourth quarter and full-year 2023 financial results and recent portfolio
execution. |
| • | Individuals
interested in participating in the call via telephone may register here. Upon registration,
all telephone participants will receive a confirmation email detailing how to join the conference
call, including the dial-in number along with a unique passcode and registrant ID that can
be used to access the call. To access the webcast, please visit the Investors and Media section
of Kiniksa’s website. A replay of the event will also be available on Kiniksa’s
website within approximately 48 hours after the event. |
About Kiniksa
Kiniksa is a commercial-stage biopharmaceutical
company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating
diseases with significant unmet medical need. Kiniksa’s immune-modulating assets, ARCALYST, abiprubart, and mavrilimumab, are based
on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and
offer the potential for differentiation. For more information, please visit www.kiniksa.com.
About ARCALYST
ARCALYST is a weekly, subcutaneously injected recombinant dimeric fusion protein that blocks interleukin-1
alpha (IL-1α) and interleukin-1 beta (IL-1β) signaling. ARCALYST was discovered by Regeneron Pharmaceuticals, Inc. (Regeneron)
and is approved by the U.S. Food and Drug Administration (FDA) for recurrent pericarditis, cryopyrin-associated periodic syndromes (CAPS),
including Familial Cold Autoinflammatory Syndrome and Muckle-Wells Syndrome, and deficiency of IL-1 receptor antagonist (DIRA). The FDA
granted Breakthrough Therapy designation to ARCALYST for the treatment of recurrent pericarditis in 2019 and Orphan Drug exclusivity
to ARCALYST in 2021 for the treatment of recurrent
pericarditis and reduction in risk of recurrence in adults and pediatric patients 12 years
and older. The European Commission granted Orphan Drug Designation to ARCALYST for the treatment
of idiopathic pericarditis in 2021.
IMPORTANT
SAFETY INFORMATION ABOUT ARCALYST
| • | ARCALYST
may affect your immune system and can lower the ability of your immune system to fight infections.
Serious infections, including life-threatening infections and death, have happened in patients
taking ARCALYST. If you have any signs of an infection, call your doctor right away. Treatment
with ARCALYST should be stopped if you get a serious infection. You should not begin treatment
with ARCALYST if you have an infection or have infections that keep coming back (chronic
infection). |
| • | While
taking ARCALYST, do not take other medicines that block interleukin-1, such as Kineret®
(anakinra), or medicines that block tumor necrosis factor, such as Enbrel®
(etanercept), Humira® (adalimumab), or Remicade® (infliximab),
as this may increase your risk of getting a serious infection. |
| • | Talk
with your doctor about your vaccine history. Ask your doctor whether you should receive any
vaccines before you begin treatment with ARCALYST. |
| • | Medicines
that affect the immune system may increase the risk of getting cancer. |
| • | Stop
taking ARCALYST and call your doctor or get emergency care right away if you have any symptoms
of an allergic reaction. |
| • | Your
doctor will do blood tests to check for changes in your blood cholesterol and triglycerides. |
| • | Common
side effects include injection-site reactions (which may include pain, redness, swelling,
itching, bruising, lumps, inflammation, skin rash, blisters, warmth, and bleeding at the
injection site), upper respiratory tract infections, joint and muscle aches, rash, ear infection,
sore throat, and runny nose. |
For
more information about ARCALYST, talk to your doctor and see the Product Information.
About Abiprubart
Abiprubart
is an investigational humanized monoclonal antibody that binds to CD40 and is designed to inhibit the CD40-CD154 (CD40 ligand) interaction,
a key T-cell co-stimulatory signal critical for B-cell maturation and immunoglobulin class switching and Type 1 immune responses. Kiniksa
believes disrupting the CD40-CD154 co-stimulatory interaction is an attractive approach to addressing multiple autoimmune disease pathologies.
About Mavrilimumab
Mavrilimumab
is an investigational fully human monoclonal antibody that blocks activity of GM-CSF by specifically binding to the alpha subunit of
the GM-CSF receptor (GM-CSFRα). Phase 2 clinical trials of mavrilimumab in rheumatoid arthritis and giant cell arteritis achieved
their primary and secondary endpoints with statistical significance. Kiniksa is evaluating potential partnership opportunities for mavrilimumab.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward looking
statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,”
“could,” “intend,” “target,” “project,” “contemplate,” “believe,”
“estimate,” “predict,” “potential” or “continue” or the negative of these terms or other
similar expressions, although not all forward-looking statements contain these identifying words. All statements contained in this press
release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation,
statements regarding: our expectation that ARCALYST 2024 net product revenue will be between $360 million and $380 million; our plan
to report data from Cohort 4 of our Phase 2 clinical trial of abiprubart in rheumatoid arthritis and a new development indication for
abiprubart in April 2024; our expectation about our cash reserves funding our current operating plan into at least 2027; our expectation
that we will help an increasing number of patients in the future; our plan to develop abiprubart in an additional indication; our plan
to present a poster at the upcoming American College of Cardiology Scientific Session in April 2024; our beliefs about the mechanisms
of our product candidates and potential impact of their approach, including that using abiprubart to disrupt the CD40-CD154 co-stimulatory
interaction is an attractive approach to address multiple autoimmune disease pathologies; and our belief that all of our product candidates
offer the potential for differentiation.
These forward-looking statements are
based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown
risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different
from any future results, performance or achievements expressed or implied by the forward-looking statements, including without limitation,
the following: delays or difficulty in enrollment of patients in, and activation or continuation of sites for, our clinical trials; delays
or difficulty in completing our clinical trials as originally designed; potential for changes between final data and any preliminary,
interim, top-line or other data from clinical trials; our inability to replicate results from our earlier clinical trials or studies;
impact of additional data from us or other companies, including the potential for our data to produce negative, inconclusive or commercially
uncompetitive results; potential undesirable side effects caused by our products and product candidates; our inability to demonstrate
safety and efficacy to the satisfaction of applicable regulatory authorities; potential for applicable regulatory authorities to not
accept our filings, delay or deny approval of any of our product candidates or require additional data or trials to support approval;
inability to successfully execute on our commercial strategy for ARCALYST; our reliance on third parties as the sole source of supply
of the drug substance and drug product used in our products and product candidates; our reliance on Regeneron as the current sole manufacturer
of ARCALYST; risks arising from our ongoing technology transfer of ARCALYST drug substance manufacturing; raw material, important ancillary
product and drug substance and/or drug product shortages; our reliance on third parties to conduct research, clinical trials, and/or
certain regulatory activities for our product candidates; complications in coordinating requirements, regulations and guidelines of regulatory
authorities across jurisdictions for our clinical trials; changes in our operating plan, business development strategy or funding requirements;
and existing or new competition.
These and other important factors discussed
in our filings with the U.S. Securities and Exchange Commission, including under the caption “Risk Factors” contained therein,
could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any
such forward-looking statements represent management’s estimates as of the date of this press release. Except as required by law,
we disclaim any intention or obligation to update or revise any forward-looking statements. These forward-looking statements should not
be relied upon as representing our views as of any date subsequent to the date of this press release.
ARCALYST® is a registered
trademark of Regeneron. All other trademarks are the property of their respective owners.
Every Second Counts!
®
Kiniksa Investor and Media Contact
Rachel Frank
(339) 970-9437
rfrank@kiniksa.com
KINIKSA PHARMACEUTICALS, LTD.
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except share and per share amounts)
(Unaudited)
| | |
Three Months Ended | | |
Years Ended | |
| | |
December 31, | | |
December 31, | |
| | |
2023 | | |
2022 | | |
2023 | | |
2022 | |
| Revenue: | |
| | | |
| | | |
| | | |
| | |
| Product revenue, net | |
$ | 71,220 | | |
$ | 39,939 | | |
$ | 233,176 | | |
$ | 122,524 | |
| License and collaboration revenue | |
| 12,175 | | |
| 21,945 | | |
| 37,083 | | |
| 97,656 | |
| Total revenue | |
| 83,395 | | |
| 61,884 | | |
| 270,259 | | |
| 220,180 | |
| Operating expenses: | |
| | | |
| | | |
| | | |
| | |
| Cost of goods sold | |
| 9,584 | | |
| 6,710 | | |
| 33,407 | | |
| 22,895 | |
| Collaboration expenses | |
| 16,939 | | |
| 7,522 | | |
| 56,524 | | |
| 24,071 | |
| Research and development | |
| 20,052 | | |
| 14,390 | | |
| 76,097 | | |
| 65,490 | |
| Selling, general and administrative | |
| 36,739 | | |
| 27,215 | | |
| 129,427 | | |
| 97,951 | |
| Total operating expenses | |
| 83,314 | | |
| 55,837 | | |
| 295,455 | | |
| 210,407 | |
| Income (loss) from operations | |
| 81 | | |
| 6,047 | | |
| (25,196 | ) | |
| 9,773 | |
| Other income | |
| 2,369 | | |
| 794 | | |
| 8,544 | | |
| 1,253 | |
| Income (loss) before income taxes | |
| 2,450 | | |
| 6,841 | | |
| (16,652 | ) | |
| 11,026 | |
| Benefit (provision) for income taxes | |
| 22,787 | | |
| (2,380 | ) | |
| 30,736 | | |
| 172,337 | |
| Net income | |
$ | 25,237 | | |
$ | 4,461 | | |
$ | 14,084 | | |
$ | 183,363 | |
| Net income per share attributable to common shareholders—basic | |
$ | 0.36 | | |
$ | 0.06 | | |
$ | 0.20 | | |
$ | 2.64 | |
| Net income per share attributable to common shareholders—diluted | |
| 0.35 | | |
| 0.06 | | |
| 0.20 | | |
| 2.60 | |
| Weighted average common shares outstanding—basic | |
| 70,371,601 | | |
| 69,609,342 | | |
| 70,058,952 | | |
| 69,382,275 | |
| Weighted average common shares outstanding—diluted | |
| 72,660,171 | | |
| 71,369,394 | | |
| 71,922,915 | | |
| 70,421,322 | |
KINIKSA PHARMACEUTICALS, LTD.
SELECTED CONSOLIDATED BALANCE SHEET DATA
(In thousands)
(Unaudited)
| | |
As of | |
| | |
December 31, | | |
December 31, | |
| | |
2023 | | |
2022 | |
| Cash, cash equivalents, and short-term investments | |
$ | 206,371 | | |
$ | 190,608 | |
| Working capital | |
| 212,631 | | |
| 195,994 | |
| Total assets | |
| 526,322 | | |
| 459,672 | |
| Accumulated deficit | |
| (477,950 | ) | |
| (492,034 | ) |
| Total shareholders' equity | |
| 438,839 | | |
| 396,149 | |
v3.24.0.1
| X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
| Name: |
dei_AmendmentFlag |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
| Name: |
dei_DocumentPeriodEndDate |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:dateItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
| Name: |
dei_DocumentType |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:submissionTypeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
| Name: |
dei_EntityAddressAddressLine1 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 2 such as Street or Suite number
| Name: |
dei_EntityAddressAddressLine2 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
+ References
+ Details
| Name: |
dei_EntityAddressCityOrTown |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionISO 3166-1 alpha-2 country code.
| Name: |
dei_EntityAddressCountry |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:countryCodeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCode for the postal or zip code
| Name: |
dei_EntityAddressPostalZipCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityCentralIndexKey |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:centralIndexKeyItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionIndicate if registrant meets the emerging growth company criteria. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityEmergingGrowthCompany |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
| Name: |
dei_EntityFileNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:fileNumberItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
| Name: |
dei_EntityIncorporationStateCountryCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarStateCountryItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityRegistrantName |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityTaxIdentificationNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:employerIdItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionLocal phone number for entity.
| Name: |
dei_LocalPhoneNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
| Name: |
dei_PreCommencementIssuerTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
| Name: |
dei_PreCommencementTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTitle of a 12(b) registered security. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
| Name: |
dei_Security12bTitle |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:securityTitleItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the Exchange on which a security is registered. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
| Name: |
dei_SecurityExchangeName |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarExchangeCodeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Section 14a
-Number 240
-Subsection 12
| Name: |
dei_SolicitingMaterial |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
| Name: |
dei_TradingSymbol |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:tradingSymbolItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
| Name: |
dei_WrittenCommunications |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
Kiniksa Pharmaceuticals (NASDAQ:KNSA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kiniksa Pharmaceuticals (NASDAQ:KNSA)
Historical Stock Chart
From Apr 2023 to Apr 2024
